Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- REVIRAL 1Independent statistical analysis of A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.: primary endpoint results, effect estimate with confidence interval, sample-size…
- Revitalize Cognition: Near Infrared Stimulation in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Revitalize Cognition: Near Infrared Stimulation in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02582593).
- Revlimid in Transfusion Dependent Patients: Complete Statistical AnalysisIndependent statistical analysis of Revlimid in Transfusion Dependent Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01178814).
- Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01600053).
- RHA® 4 NLF Cannula: Complete Statistical AnalysisIndependent statistical analysis of RHA® 4 NLF Cannula: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04754646).
- RHA® Redensity Eye Versus No-treatment for the Infra-Orbital Hollows: Complete Statistical AnalysisIndependent statistical analysis of RHA® Redensity Eye Versus No-treatment for the Infra-Orbital Hollows: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04577898).
- RHAPSODYIndependent statistical analysis of Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- RHINTRACIndependent statistical analysis of RhinAer Procedure for Treatment of Chronic Rhinitis Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04533438).
- RI-US XLIndependent statistical analysis of Resolute Integrity US Extended Length Sub-Study(RI US XL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01913600).
- RICHIndependent statistical analysis of Repair of Infected or Contaminated Hernias: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00617357).
- Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy: Complete Statistical AnalysisIndependent statistical analysis of Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03176472).
- Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RIDILOTT-DVTIndependent statistical analysis of Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03413618).
- Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease: Complete Statistical AnalysisIndependent statistical analysis of Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RIFL (Rigid and Flexing Laryngoscope) vs. Fiberoptic Bronchoscope: Complete Statistical AnalysisIndependent statistical analysis of RIFL (Rigid and Flexing Laryngoscope) vs. Fiberoptic Bronchoscope: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01965938).
- RIGHT: Rhythm ID Going Head-to-Head Trial: Complete Statistical AnalysisIndependent statistical analysis of RIGHT: Rhythm ID Going Head-to-Head Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00148954).
- RiLEYIndependent statistical analysis of 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Riluzole in the Treatment of Bipolar Depression: Complete Statistical AnalysisIndependent statistical analysis of Riluzole in the Treatment of Bipolar Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00544544).
- Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders: Complete Statistical AnalysisIndependent statistical analysis of Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RIM4DMDIndependent statistical analysis of Rimeporide in Patients With Duchenne Muscular Dystrophy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02710591).
- RIPCOM1Independent statistical analysis of The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RISEIndependent statistical analysis of Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RISE AdultIndependent statistical analysis of RISE Adult Medication Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01779362).
- RISE-MIndependent statistical analysis of Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03634800).
- RISE-UPIndependent statistical analysis of Risk Information and Skin-cancer Education for Undergraduate Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03979872).
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer: Complete Statistical AnalysisIndependent statistical analysis of Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RITA-2Independent statistical analysis of Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RITAPSIndependent statistical analysis of A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom’s Macroglobulinemia: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM): Complete Statistical AnalysisIndependent statistical analysis of Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH): Complete Statistical AnalysisIndependent statistical analysis of Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01086540).
- Rituximab in Pretreated Elderly or Unfit B-CLL Patients: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Pretreated Elderly or Unfit B-CLL Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01576588).
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Rituximab in Treating Patients With Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Treating Patients With Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003820).
- Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells: primary endpoint results, effect estimate with confidence…
- Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RIVALIndependent statistical analysis of A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- RJIndependent statistical analysis of RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RLSIndependent statistical analysis of Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RLS-PractiseIndependent statistical analysis of Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…